Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.

Yu J, Shi S, Li M, Fang Q, Yan J, Zhang Y, Liu Z, Li Z, Wang L, Lv Z, Wang Y, Wang T, Zhao Z, Ma X, Zhang J, Xie G, Sun H, Zhao N, Chang A, Feng Y, Wang H, Chen X, Liang Y, Zhao T, Wang J, Ma W, Gao C, Gao S, Wang B, Xie Y, Zhou T, Yang C, Wang X, Hao J

Open source

DOI: 10.1038/s41392-026-02966-0
Published: 2026 Nov 3
Container: Signal transduction and targeted therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41392-026-02966-0,
  title = {Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.},
  author = {Yu J and Shi S and Li M and Fang Q and Yan J and Zhang Y and Liu Z and Li Z and Wang L and Lv Z and Wang Y and Wang T and Zhao Z and Ma X and Zhang J and Xie G and Sun H and Zhao N and Chang A and Feng Y and Wang H and Chen X and Liang Y and Zhao T and Wang J and Ma W and Gao C and Gao S and Wang B and Xie Y and Zhou T and Yang C and Wang X and Hao J},
  year = {2026},
  journal = {Signal transduction and targeted therapy},
  doi = {10.1038/s41392-026-02966-0},
  url = {https://doi.org/10.1038/s41392-026-02966-0}
}

RIS

TY  - JOUR
TI  - Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.
AU  - Yu J
AU  - Shi S
AU  - Li M
AU  - Fang Q
AU  - Yan J
AU  - Zhang Y
AU  - Liu Z
AU  - Li Z
AU  - Wang L
AU  - Lv Z
AU  - Wang Y
AU  - Wang T
AU  - Zhao Z
AU  - Ma X
AU  - Zhang J
AU  - Xie G
AU  - Sun H
AU  - Zhao N
AU  - Chang A
AU  - Feng Y
AU  - Wang H
AU  - Chen X
AU  - Liang Y
AU  - Zhao T
AU  - Wang J
AU  - Ma W
AU  - Gao C
AU  - Gao S
AU  - Wang B
AU  - Xie Y
AU  - Zhou T
AU  - Yang C
AU  - Wang X
AU  - Hao J
PY  - 2026
JO  - Signal transduction and targeted therapy
DO  - 10.1038/s41392-026-02966-0
UR  - https://doi.org/10.1038/s41392-026-02966-0
ER  -

APA

J, Y., S, S., M, L., Q, F., J, Y., Y, Z., Z, L., Z, L., L, W., Z, L., Y, W., T, W., Z, Z., X, M., J, Z., G, X., H, S., N, Z., A, C., Y, F., H, W., X, C., Y, L., T, Z., J, W., W, M., C, G., S, G., B, W., Y, X., T, Z., C, Y., X, W., & J, H. (2026). Sitagliptin, a repurposed diabetes drug, overcomes gemcitabine resistance in pancreatic cancer via ribonucleotide reductase inhibition: SITGEM-CARE phase 2 trial.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02966-0

Source records

pubmed · retrieved 2026-11-10T18:53:07.816Z